{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:23:43Z","timestamp":1792715023878,"version":"4.5.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Several studies have identified mutations in the MYD88L265P gene as a key driver mutation in several B-cell lymphomas. B-cell lymphomas that harbor the MYD88L265P mutation form a complex with phosphorylated Bruton\u2019s tyrosine kinase (BTK) and are responsive to BTK inhibition. However, BTK inhibition in B-cell lymphomas rarely results in a complete response and most patients experience eventual disease relapse. Persistent survival signaling though downstream molecules such as interleukin 1 receptor-associated kinase 4 (IRAK-4), an integral part of the \u201cmyddosome\u201d complex, has been shown to be constitutively active in B-cell lymphoma patients treated with BTK inhibitors. Emerging evidence is demonstrating the therapeutic benefit of IRAK-4 inhibition in B-cell lymphomas, along with possibly reversing BTK inhibitor resistance. While MYD88 gene mutations are not present in myeloid malignancies, downstream overexpression of the oncogenic long form of IRAK-4 has been found in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), particularly in AML and MDS that harbor mutations in splicing factors U2AF1 and SF3B1. These data suggest that the anti-leukemic activity of IRAK-4 inhibition can be exploited in relapsed\/refractory (R\/R) AML\/MDS. In this review article, we discuss the currently available pre-clinical and clinical data of emavusertib, a selective, orally bioavailable IRAK-4 inhibitor in the treatment of R\/R B-cell lymphomas and myeloid malignancies.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1239082","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:15:56Z","timestamp":1698714956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies"],"prefix":"10.3389","volume":"14","author":[{"given":"Ricardo D.","family":"Parrondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Von Roemeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Von Roemeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","article-title":"Pathogenesis of human B cell lymphomas","volume":"30","author":"Shaffer","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-844654","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nri3446","article-title":"The history of Toll-like receptors - redefining innate immunity","volume":"13","author":"O'Neill","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00390","article-title":"The role of toll-like receptors in hematopoietic Malignancies","volume":"7","author":"Monlish","year":"2016","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/imr.12792","article-title":"Pathogenic B-cell receptor signaling in lymphoid Malignancies: New insights to improve treatment","volume":"291","author":"Young","year":"2019","journal-title":"Immunol Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-019-0314-5","article-title":"U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid Malignancies","volume":"21","author":"Smith","year":"2019","journal-title":"Nat Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-052909-141507","article-title":"Structural biology of the Toll-like receptor family","volume":"80","author":"Kang","year":"2011","journal-title":"Annu Rev Biochem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0318-096R","article-title":"Understanding early TLR signaling through the Myddosome","volume":"105","author":"Balka","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/351355b0","article-title":"Drosophila toll and IL-1 receptor","volume":"351","author":"Gay","year":"1991","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80136-7","article-title":"MyD88 is an adaptor protein in the hToll\/IL-1 receptor family signaling pathways","volume":"2","author":"Medzhitov","year":"1998","journal-title":"Mol Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301742200","article-title":"Structural complementarity of Toll\/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88","volume":"278","author":"Dunne","year":"2003","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.20.12203","article-title":"MyD88, an adapter protein involved in interleukin-1 signaling","volume":"273","author":"Burns","year":"1998","journal-title":"J Biol Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nature09121","article-title":"Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR\/IL-1R signalling","volume":"465","author":"Lin","year":"2010","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5343.1612","article-title":"IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling","volume":"278","author":"Muzio","year":"1997","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M102262200","article-title":"IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFkappa B","volume":"276","author":"Qian","year":"2001","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80402-1","article-title":"MyD88: an adapter that recruits IRAK to the IL-1 receptor complex","volume":"7","author":"Wesche","year":"1997","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.8.3910","article-title":"Regulation of IL-1 receptor-associated kinases by lipopolysaccharide","volume":"168","author":"Hu","year":"2002","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.071054198","article-title":"IL-1-induced NFkappa B and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK)","volume":"98","author":"Li","year":"2001","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B cell antigen receptor signaling 101","volume":"41","author":"Dal Porto","year":"2004","journal-title":"Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMc1211959","article-title":"MYD88 L265P somatic mutation in IgM MGUS","volume":"367","author":"Landgren","year":"2012","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-530659","article-title":"Primary testicular lymphoma","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"Gonzalez-Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09176.x","article-title":"MYD88 somatic mutations in MALT lymphomas","volume":"158","author":"Li","year":"2012","journal-title":"Br J Haematology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0215","article-title":"MYD88 L265P mutation in lymphoid Malignancies","volume":"78","author":"Yu","year":"2018","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100095","article-title":"Structure, function and regulation of the Toll\/IL-1 receptor adaptor proteins","volume":"85","author":"Watters","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006783","article-title":"Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid Malignancies","volume":"138","author":"Stephens","year":"2021","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.4004.4004","article-title":"Targeting IRAK1\/IRAK4 signaling in Waldenstrom's macroglobulinemia","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-030518-055734","article-title":"Taming the heterogeneity of aggressive lymphomas for precision therapy","volume":"3","author":"Young","year":"2019","journal-title":"Annu Rev Cancer Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151074","article-title":"Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid Malignancy","volume":"212","author":"Kelly","year":"2015","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-543306","article-title":"Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome","volume":"123","author":"Mart\u00ednez-Trillos","year":"2014","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0507-8","article-title":"Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia","volume":"34","author":"Gim\u00e9nez","year":"2020","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15714","article-title":"MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL","volume":"184","author":"Improgo","year":"2019","journal-title":"Br J Haematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23545","article-title":"Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia","volume":"88","author":"Poulain","year":"2013","journal-title":"Am J Hematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.8","article-title":"Clonal B cells in Waldenstr\u00f6m\u2019s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling","volume":"30","author":"Argyropoulos","year":"2016","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discovery"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.c.6533101","article-title":"Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases","volume":"29","author":"Von Roemeling","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"New Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.054080","article-title":"BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-21-P073","article-title":"Abstract P073: Pharmacological inhibition of IRAK4 with CA-4948 is beneficial in marginal zone lymphoma models with secondary resistance to PI3K and BTK inhibitors","volume":"20","author":"Guidetti","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-011-0019-7","article-title":"Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling","volume":"34","author":"Pighi","year":"2011","journal-title":"Cell Oncol (Dordr)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05883.x","article-title":"Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma","volume":"132","author":"Rinaldi","year":"2006","journal-title":"Br J Haematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"New Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27792","article-title":"Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140857","article-title":"Safety, pharmacokinetics and activity of CA-4948, an IRAK4 inhibitor, for treatment of patients with relapsed or refractory hematologic Malignancies: results from the phase 1 study","volume":"136","author":"Nowakowski","year":"2020","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124458","article-title":"SF3B1 mutations induce oncogenic IRAK4 isoforms and activate targetable innate immune pathways in MDS and AML","volume":"134","author":"Choudhary","year":"2019","journal-title":"Blood"},{"key":"B66","volume-title":"Unpublished investigator brochure, Version 2","year":"2018"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.0c00255","article-title":"Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic Malignancies","volume":"11","author":"Gummadi","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020399","article-title":"Targeting IRAK4 with emavusertib in lymphoma models with secondary resistance to PI3K and BTK inhibitors","volume":"12","author":"Guidetti","year":"2023","journal-title":"J Clin Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-1168","article-title":"Abstract 1168: Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma","volume":"77","author":"Booher","year":"2017","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-4798","article-title":"Abstract 4798: Efficacy and safety of highly selective novel IRAK4 inhibitors for treatment of ABC-DLBCL","volume":"76","author":"Balasubramanian","year":"2016","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0305","article-title":"Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells","volume":"12","author":"Gunawardane","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.168","article-title":"Phase 1 study of CA-4948, a novel inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) in patients with R\/R non-hodgkin lymphoma (NHL); poster: ABCL-350","volume":"19","author":"Younes","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-385","article-title":"Abstract 385: Identification of NF-kappaB phospho-p50 as a predictive biomarker for IRAK4 inhibitor CA-4948 in patients with non-Hodgkin's lymphoma","volume":"81","author":"Ugolkov","year":"2021","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7575","article-title":"Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic Malignancies","volume":"40","author":"Joffe","year":"2022","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac209.266","article-title":"CTIM-34. PRELIMINARY SAFETY AND EFFICACY DATA ON TWO PATIENTS WITH RELAPSED\/REFRACTORY CNS LYMPHOMA TREATED WITH EMAVUSERTIB (CA-4948) AND IBRUTINIB COMBINATION: A SUBSET ANALYSIS OF TAKEAIM LYMPHOMA TRIAL","volume":"24","author":"Iqbal","year":"2022","journal-title":"Neuro-Oncology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nm.2054","article-title":"Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype","volume":"16","author":"Starczynowski","year":"2010","journal-title":"Nat Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141898","article-title":"Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling","volume":"212","author":"Varney","year":"2015","journal-title":"J Exp Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","article-title":"IRAK1 and IRAK4 as emerging therapeutic targets in hematologic Malignancies","volume":"29","author":"Bennett","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"PS991","DOI":"10.1097\/01.HS9.0000562260.56570.c7","article-title":"PS991 CA-4948, AN IRAK4\/FLT3 INHIBITOR, SHOWS ANTILEUKEMIC ACTIVITY IN MOUSE MODELS OF FLT3 WILD-TYPE AND FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML)","volume":"3","author":"Booher","year":"2019","journal-title":"HemaSphere"},{"key":"B80","article-title":"A phase 1, dose escalation trial with novel oral IRAK4 inhibitor CA-4948 in patients with acute myelogenous leukemia or myelodysplastic syndrome \u2013 interim report","volume-title":"HemaSphere","author":"Garcia-Manero","year":"2021"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843408.31385.3f","article-title":"S129: TAKEAIM LEUKEMIA- A PHASE 1\/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED\/REFRACTORY AML OR MDS","volume":"6","author":"Garcia-Manero","year":"2022","journal-title":"HemaSphere"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7016","article-title":"Phase 1\/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed\/refractory (R\/R) acute myeloid leukemia or lyelodysplastic syndrome","volume":"40","author":"Garcia-Manero","year":"2022","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000844780.60464.3e","article-title":"P473: DEVELOPMENT OF POTENTIAL BIOMARKERS FOR IRAK4 INHIBITOR EMAVUSERTIB IN HUMAN ACUTE MYELOID LEUKEMIA","volume":"6","author":"Ugolkov","year":"2022","journal-title":"HemaSphere"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K-\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold","year":"2019","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell Malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell Malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.12","article-title":"B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies","volume":"28","author":"Bojarczuk","year":"2014","journal-title":"Leukemia"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124297","article-title":"A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-hodgkin's lymphoma: long-term follow-up, final analysis","volume":"134","author":"Jurczak","year":"2019","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv102","article-title":"A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma","volume":"26","author":"Witzig","year":"2015","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119805","article-title":"A clinical study of tomaralimab (OPN-305), a toll-like receptor 2 (TLR-2) antibody, in heavily pre-treated transfusion dependent patients with lower risk myelodysplastic syndromes (MDS) that have received and failed on prior hypomethylating agent (HMA) therapy","volume":"132","author":"Garcia-Manero","year":"2018","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-407999","article-title":"Cytotoxic effects of bortezomib in myelodysplastic syndrome\/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1","volume":"120","author":"Fang","year":"2012","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24746","article-title":"An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes","volume":"92","author":"Daher","year":"2017","journal-title":"Am J Hematol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","article-title":"Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome","volume":"24","author":"Rhyasen","year":"2013","journal-title":"Cancer Cell"},{"key":"B95","first-page":"EP390","article-title":"IRAK4 inhibitor CA-4948 potentiates antitumor effects of azacitidine and venetoclax in human acute myeloid leukemia","volume":"5","author":"Ugolkov A","year":"2021","journal-title":"HemaSphere"},{"key":"B96","article-title":"IRAK4 inhibitor CA-4948 potentiates antitumor effects of azacitidine and venetoclax in human acute myeloidleukemia","volume":"5","author":"Bennett","year":"2021","journal-title":"HemaSphere"},{"key":"B97","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41467-021-27928-8","article-title":"Eliminating chronic myeloid leukemia stem cells by IRAK1\/4 inhibitors","volume":"13","author":"Tanaka","year":"2022","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1239082\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:16:01Z","timestamp":1698714961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1239082\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":97,"alternative-id":["10.3389\/fimmu.2023.1239082"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1239082","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"article-number":"1239082"}}